Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma | Zendy

Noopur Raje | Zendy; Jesús G. Berdeja | Zendy; Yi Lin | Zendy; David S. Siegel | Zendy; Sundar Jagannath | Zendy; Deepu Madduri | Zendy; Michaela Liedtke | Zendy; Jacalyn Rosenblatt | Zendy; Marcela V. Maus | Zendy; Ashley Turka | Zendy; Lyh-Ping Lam | Zendy; Richard A. Morgan | Zendy; Kevin M. Friedman | Zendy; Monica Massaro | Zendy; Julie Wang | Zendy; Greg Russotti | Zendy; Zhihong Yang | Zendy; Timothy Campbell | Zendy; Kristen Hege | Zendy; Fabio Petrocca | Zendy; M. Travis Quigley | Zendy; Nikhil C. Munshi | Zendy; James N. Kochenderfer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

Author(s) -

Noopur Raje,

Jesús G. Berdeja,

Yi Lin,

David S. Siegel,

Sundar Jagannath,

Deepu Madduri,

Michaela Liedtke,

Jacalyn Rosenblatt,

Marcela V. Maus,

Ashley Turka,

Lyh-Ping Lam,

Richard A. Morgan,

Kevin M. Friedman,

Monica Massaro,

Julie Wang,

Greg Russotti,

Zhihong Yang,

Timothy Campbell,

Kristen Hege,

Fabio Petrocca,

M. Travis Quigley,

Nikhil C. Munshi,

James N. Kochenderfer

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1817226

Subject(s) - chimeric antigen receptor , car t cell therapy , multiple myeloma , cancer research , medicine , antigen , cell therapy , refractory (planetary science) , oncology , immunology , cell , t cell , biology , immune system , genetics , astrobiology

Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of multiple myeloma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research